In addition, results from the phase 3 AURA3 trial demonstrated the superiority of osimertinib over standard platinum-based treatment of NSCLC patients with EGFR T790M mutation relapsed or refractory to first-line EGFR TKI therapy, thus definitively establishing this third-generation TKI as current standard treatment [15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.